The world's leading provider of life sciences research cloud solutions provider Medidata and China's leading pharmaceutical company Zhejiang Haizheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Haizheng Pharmaceutical") announced today that further expansion of cooperation, Haizheng Pharmaceutical will adopt more Extensive Medidata technology enhances the quality and operational efficiency of new drug research data in China.
Since 2015, Hisun Pharmaceutical has adopted Medidata's world-leading Medidata RaveTM, a global leader in collecting, managing and reporting patient data, significantly reducing the cost of previous research. Today, the company will further use Medidata Balance to integrate randomized distribution and trial supply management (RTSM) with electronic data collection (EDC) into one system to proactively address research performance issues, streamline operational processes, and improve clinical trial quality. .
Mr. Zhang Hai, Director of Clinical Operations of Hisun Pharmaceutical, said: “Medidata's EDC, Management and Reporting System is a comprehensive and proven solution that helps us achieve real-time control of research performance and ensure that trials are available at home and abroad. Regulatory review. We are confident that by expanding the use of Medidata Balance, which seamlessly integrates with Rave, we can further reduce data coordination costs between EDC and Interactive Network Response (iWRS), shorten data entry time, and improve test quality and operation. effectiveness."
Founded in 1956, Haizheng Pharmaceutical Co., Ltd. is headquartered in Taizhou City, Zhejiang Province. Hisun Pharmaceutical is committed to integrating drug development and production resources to provide better products and services to customers around the world. The company's research and development and production of pharmaceutical treatment areas include anti-tumor, anti-infective, cardiovascular, endocrine, immunosuppressive, anti-depressant, orthopedics.
Mr. Huang Guiping, Vice President of Operations, Asia Pacific, Medidata, said: “The cooperation between Medidata and Hisun Pharmaceuticals reflects our common vision of always adhering to the mission of “Persistence in Drug Innovation and Achieving Healthy Dreams.†We are very pleased that Medidata will Continue to provide important support to Hisun Pharmaceutical to help them bring new drugs and treatments to patients as soon as possible."
About Zhejiang Haizheng Pharmaceutical Co., Ltd.
Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. (stock code 600267) adheres to the mission of “Persistence in Drug Innovation, Achieving Healthy Dreams†and the vision of “becoming a well-respected global professional pharmaceutical company†and is committed to integration. Drug research and development and production resources, to provide better products and services to customers around the world, through the US FDA, EU EDQM, Australia TGA, South Korea KFDA and other officially certified varieties of more than 40, sold to more than 40 countries and regions around the world.
About Medidata
Medidata is the world's leading provider of cloud solutions for life sciences clinical research, improving clinical development through its advanced applications and electronic data analysis. We are committed to helping our global customers advance their market competition and scientific research goals. Our clients include: more than 950 global pharmaceutical companies, biotechnology, diagnostic and medical device companies, leading academic medical centers and contract research organizations (CROs). Our industry-leading cloud technology platform, Medidata Clinical Cloud, is the leading technology solution for 18 of the world's top 25 pharmaceutical companies and 18 of the world's top 25 medical device companies in clinical trials. Prospective drug therapy clinical trials have improved efficiency and quality, resulting in improved design, planning, and implementation, management, and reporting.
Nucleic Acid (DNA/RNA) Extraction Kit
1. Introduction
The total viral nucleic acid extraction kit is suitable for extracting total viral nucleic acid from serum, plasma, tissue homogenate and other samples. The kit is based on silica column purification technology, which eliminates the need for toxic phenol-chloroform extraction and time-consuming alcohol precipitation. This product has successfully extracted nucleic acids from hepatitis B A/C, hepatitis C, and norovirus standard. The obtained DNA/RNA can be directly used in a series of downstream experiments such as PCR, RT-PCR, and LAMP.
Notice:
1. The carrier RNA solid must be dissolved in Nuclease Free Water to 1µg/µl before use, and vortex to dissolve. Store in aliquots at -70°C. If you need to store it at -20℃ for a long time, please repackage it according to the number of times of use.
2. Dissolve Proteinase K (20mg/ml): Add Proteinase Dissolve Buffer to dissolve Proteinase K to a final concentration of 20mg/ml. Proteinase K dry powder can be stored at 2-8°C for one year, but dissolved Proteinase K must be stored in aliquots at -20°C. Repeated freezing and thawing of Proteinase K can affect its activity.
3. Buffer VHB must be diluted with 14 ml absolute ethanol before use and stored at room temperature.
4. Buffer RW2 must be diluted with 80 ml of absolute ethanol before use and stored at room temperature.
3. Shelf life
Except for Proteinase K and Carrier RNA, other components of this product can be stored at room temperature (15-25°C) for 12 months, and should be stored at 2-8°C for long-term storage. Proteinase K and Carrier RNA dry powder are transported at room temperature. Please store at -20°C after receiving the test product, and store at -20°C after dissolving.
Nucleic Acid Extraction Reagent Kit,Nucleic Acid Extraction Kit,Covid-19 Nucleic Acid Extraction Reagents,Nucleic Acid Test Kits
Jilin Sinoscience Technology Co. LTD , https://www.jilinsinoscience.com